Abstract Background There is increasing interest in enhancing the response of the PARP inhibitor olaparib. which is currently approved for pancreatic ductal adenocarcinoma (PDAC) patients with defects in DNA damage repair associated with germline BRCA1/2 mutations. Moreover. agents that can mimic these defects in the absence of germline BRCA1/2 mutations are an area of active research... https://hollandscountryclothinges.shop/product-category/horse-leg-straps/